HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
C9214 | Bevacizumab | Avastin | 10 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Feb 26, 2004 | Dec 31, 2004 | No Longer Used | |
Q5107 | Bevacizumab-awwb | Mvasi | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2018 | Jan 1, 2019 | In Use | ||
Q5118 | Bevacizumab-bvzr | Zirabev | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2019 | Oct 1, 2019 | In Use | ||
J0207 | Amifostine | Ethyol | 500 mg | Ancillary Therapy | Chemoprotective | Detoxifying Agent | No | 1995 | Jan 1, 1998 | In Use | ||
NA | Bexarotene | Targretin | 75mg | Chemotherapy | Immunomodulator | Retinoic Acid Derivative | Yes | 2014 | In Use | |||
NA | Bicalutamide | Casodex | 50 mg | Hormonal Therapy | Androgen Receptor Inhibitor | non-steriodal | Yes | 1995 | In Use | |||
C9449 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Apr 1, 2015 | In Use | ||
J9039 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Jan 1, 2016 | In Use | ||
J9042 | Brentuximab vedotin | Adcetris | 1 mg | Immunotherapy | Drug Antibody Conjugate | CD30 | No | 2011 | Jan 1, 2013 | In Use | ||
C9287 | Brentuximab vedotin | Adcetris | 1 mg | Immunotherapy | Drug Antibody Conjugate | CD30 | No | 2011 | Jan 1, 2012 | Dec 31, 2012 | No Longer Used | |
C9073 | Brexucabtagene autileucel | Tecartus | 2000000 | Immunotherapy | CAR-T | CD19 | No | 2020 | Jan 1, 2021 | Apr 1, 2021 | In Use | |
Q2053 | Brexucabtagene autoleucel | Tecartus | 2000000 | Immunotherapy | CAR-T | CD-19 | No | 2020 | Apr 1, 2021 | In Use | ||
J9303 | Panitumumab | Vectibix | 10mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2006 | Jan 1, 2008 | In Use | ||
NA | Bromocriptine Mesylate | Parlodel | Chemotherapy | Dopamine Agonist | Ergot Derivative | Yes | 1978 | In Use | ||||
J8510 | Busulfan | Myleran | 2 mg | Chemotherapy | Alkylating Agent | Alkylsulfonate | Yes | 1954 | Jan 1, 2000 | In Use | ||
Adagrasib | Krazati | 200mg | Immunotherapy | RAS Inhibitor | KrAS G12C | Yes | 2022 | In Use | ||||
NA | Cabozantinib | Cabometyx | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
NA | Cabozantinib | Cometriq | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
NA | Crizotinib | Xalkori | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
NA | Cyclophosphamide | Cyclophosphamide oral | 50 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | In Use | |||
J9095 | Cyclophosphamide | Cyclophosphamide lyophilized | 500 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
J9096 | Cyclophosphamide | Cyclophosphamide lyophilized | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
J9094 | Cyclophosphamide | Cyclophosphamide lyophilized | 200 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
J9070 | Cyclophosphamide | Cyclophosphamide | 100 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1984 | Apr 17, 2024 | No Longer Used | |
J9208 | Ifosfamide | Ifosfamide | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1988 | Jan 1, 1999 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.